SRZN

SurrozenC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The credible bull case is that Surrozen converts from a preclinical ophthalmology story into a funded clinical-stage story: management reiterated an H2 2026 IND target for SZN-8141, ARVO provides a near-term scientific visibility point, and successful IND clearance could unlock $95.1 million of contingent PIPE proceeds that would extend runway meaningfully [#8-K-2026-03-23] [#10-K-2026-03-23].

Posture

Mixed

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta +2.3.

What can break

FDA clearance may not arrive by October 31, 2026, preventing the contingent second PIPE closing.

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $33.00 · Bull $45.00 · Bear $22.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-22 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net —

Target $42.50

Why

Momentum12 · Δ7d -4.7

Value41 · Δ7d -0.1

Sentiment94 · Δ7d +2.3

So what

Balanced signals. Wait for confirmation before sizing up.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Sentiment · See AI snapshot

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

-4.7

Δ21d

-4.5

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+2.3

Δ21d

+16.7

Why this grade

Composite grade C. Momentum 12.4 / Value 41.1 / Sentiment 93.9

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$254.96M

Beta

0.58

Shares Out

11.61M

P/E (TTM) · Derived

-0.7

P/S (TTM)

45.43

P/FCF (TTM) · Derived

-6.15

Rev YoY

+408.6%

EPS YoY

+56.7%

Gross Margin

+95.9%

Op Margin

-1055.6%

Net Debt

-$82.61M

Current Ratio

11.91

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology